MEDIPOST obtains Patent in Japan for culturing mesenchymal stem cells.
MEDIPOST completes Phase 1/2 of clinical tests of PNEUMOSTEM ®, the lung medicine for premature babies.
MEDIPOST’s joint research with LG Chem, Ltd. MEDIPOST aims at development of transgenic stem cells.
MEDIPOST enters into a sales contract of ankle joint indication Cartistem® with SK Bioland Co., Ltd.
MEDIPOST Obtains Patent in U.S. for culturing mesenchymal stem cells
MEDIPOST obtains Patent of a ‘Cartistem’-relevant composite in Mexico for treating cartilage.
MEDIPOST obtains Patent of ‘a stem cell composite in Japan for hair loss prevention.’
MEDIPOST obtains Patent in 6 countries of Europe for ‘culturing mesenchymal stem cells method’.
MEDIPOST’s achievement of ‘Cartistem’, the stem cell medicine, is thriving.
21, Daewangpangyo-ro 644 (Sampyeong-dong), Bundang-gu, Seongnam-si, Gyeonggi-do, Korea MEDIPOST Co., Ltd.TEL : 02-3465-6677
© Copyright - The Future of Biotechnology, MEDIPOST